This Review discusses the progress made by international networks in the USA, Europe and Asia towards improving the efficacy of existing and novel therapies for lupus nephritis. Strategies being actively pursued include biomarker identification and optimization of induction and maintenance treatment. These approaches aim to improve patients' outcomes by raising complete response rates, reducing renal flares, preserving long-term renal function, and minimizing treatment-related toxic effects.
